
The article presents a clinical case of arrhythmogenic right ventricular dysplasia. Modern diagnostic approaches for early intravital diagnosis of arrhythmogenic right ventricular dysplasia are analyzed using the example of the presented case of sudden death of a 58-year-old woman. Manifestations may be nonspecific, as in our case, which complicates the diagnosis of this condition. This, in turn, affects the life of the patient, his relatives and future generations. Therefore, it is necessary to conduct a thorough search for all possible causes in order not to miss this rare disease and not to delay diagnosis and treatment.
MicroRNAs (miRNAs) are crucial post-transcriptional regulators of gene expression involved in embryogenesis and cardiovascular system functioning. Specific miRNAs, such as miR-182-5p and miR-5187-5p, have been identified as differential biomarkers in coronary arteries damage. Additionally, miRNAs including miR-106b/25, -17/92a, -21/590-5p, -126*, and -45 have shown potential as predictors of unstable angina. Elevated miR-146 levels indicate platelet activation and a high risk of recurrent myocardial infarction. The regulation of mRNA functions associated with dilated and diabetic cardiomyopathies is significantly influenced by miR-21. Synthetic miRNAs are being developed as promising therapeutic agents: miR-494 for ischemic stroke, miR-33 for metabolic syndrome, and miR-44 for cerebrovascular atherosclerosis. Ongoing research is exploring miR-210 for angina treatment, while miR-494, miR-33, and miR-44 are being investigated for their roles in treating ischemic stroke, metabolic syndrome, and heart failure. Furthermore, miRNA antagonists fixed on stents are under consideration as effective tools for thrombosis prevention. Experimental miRNA regulators are being tested in regenerative cardiology, focusing on heart remodeling caused by arterial hypertension or acute myocardial infarction. This review highlights the diagnostic and therapeutic potential of miRNAs in cardiovascular medicine, emphasizing their role in personalized treatment strategies.
After the SARS-CoV-2 pandemic, the disease continues to evolve. The biggest challenge today is managing the short- and long-term complications of COVID-19. The article reviews the latest data from the global medical literature on current understanding of the wide range of cardiovascular consequences of COVID-19 with the aim of further studying their course and prevention.
The article provides a comparative overview of hepatoprotective drugs and their role in the treatment of liver pathologies. A literature review on the origin and use of hepatoprotectors in liver diseases is presented, and the effectiveness is evaluated.
The article describes and analyzes the prenatal factors and features of the clinical course, diagnosis, differential diagnosis and treatment of congenital pneumonia in newborns. Attention is focused on the criteria for early diagnosis of this pathology by neonatologists, and on the implementation of priority medical interventions to correct pathophysiological disorders that accompany congenital pneumonia in newborns. The importance of observing the continuity of medical monitoring of newborns after discharge from the hospital by a family doctor and cathartic observation in order to prevent the development of complications is emphasized. Modern strategies for the prevention of congenital pneumonia in newborns and methods of effective correction of prenatal factors in pregnant women that affect this pathology are described.